
CLAIMS

1. A compound of Formula (I'):



I'

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta};

each R^{Ta} independently is halogen, CN, -OH, $-NH_2$, -C(=O)OH, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, $-NH_2$, $-OR^{A1a}$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or $-NH_2$.

2. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta};


each R^{Ta} independently is halogen, CN, -OH, $-NH_2$, -C(=O)OH, -O-(C_1-C_6 alkylC_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, $-NH_2$, $-OR^{A1a}$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or $-NH_2$;

provided that when Z is , then Ar^1 is C_6-C_{10} aryl optionally substituted with one or more halogen.

3. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, -OR^{A1a}, or -O-(C_1-C_6 alkyl) optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is C_6-C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6-C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

4. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, -O-(C_1-C_6 alkyl), or C_1-C_6 alkyl; wherein the -O-(C_1-C_6 alkyl) or C_1-C_6 alkyl is optionally substituted with one or more halogen;


T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, -OR^{A1a}, or -O-(C_1-C_6 alkyl) optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is C_6-C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6-C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen;

provided that when Z is  , then Ar^1 is C_6-C_{10} aryl optionally substituted with one or more halogen.

5. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, -O-(C_1-C_6 alkyl), or C_1-C_6 alkyl; wherein the -O-(C_1-C_6 alkyl) or C_1-C_6 alkyl is optionally substituted with one or more halogen;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more halogen.

6. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more C_1-C_6 alkyl;

T is C_2-C_6 alkenyl optionally substituted with one or more 6-membered heterocycloalkyl; and

Ar^1 is C_6 aryl optionally substituted with one or more halogen.














7. The compound of any one of the preceding claims, wherein W is CH.


8. The compound of any one of the preceding claims, wherein Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z; and


each R^Z independently is halogen, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen.


9. The compound of any one of the preceding claims, wherein Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl,3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z.


10. The compound of any one of the preceding claims, wherein Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl,3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z.

11. The compound of any one of the preceding claims, wherein Z is , , , , , , , , , , , , .



12. The compound of any one of the preceding claims, wherein Z is 





13. The compound of any one of the preceding claims, wherein at least one R^Z is halogen.

14. The compound of any one of the preceding claims, wherein at least one R^Z is F or Cl.

15. The compound of any one of the preceding claims, wherein at least one R^Z is -O-(C_1-C_6 alkyl) optionally substituted with one or more R^{Za}.

16. The compound of any one of the preceding claims, wherein at least one R^Z is -OCH_3.

17. The compound of any one of the preceding claims, wherein at least one R^Z is C_1-C_6 alkyl.

18. The compound of any one of the preceding claims, wherein at least one R^Z is methyl, ethyl, or propyl.

19. The compound of any one of the preceding claims, wherein at least one R^Z is C_1-C_6 alkyl substituted with one or more halogen.

20. The compound of any one of the preceding claims, wherein at least one R^Z is CF_3.

21. The compound of any one of the preceding claims, wherein at least one R^Z is 3- to 10-membered heterocycloalkyl optionally substituted with one or more R^{Za}.

22. The compound of any one of the preceding claims, wherein at least one R^Z is oxetanyl.

23. The compound of any one of the preceding claims, wherein T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH_2, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta}; and

each R^{Ta} independently is halogen, CN, -OH, -NH_2, -C(=O)OH, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

24. The compound of any one of the preceding claims, wherein T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

25. The compound of any one of the preceding claims, wherein T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

26. The compound of any one of the preceding claims, wherein T is –O-(C_1-C_6 alkyl) optionally substituted with one or more R^T.

27. The compound of any one of the preceding claims, wherein T is –NH-(C_1-C_6 alkyl) optionally substituted with one or more R^T.

28. The compound of any one of the preceding claims, wherein T is C_1-C_6 alkyl optionally substituted with one or more R^T.

29. The compound of any one of the preceding claims, wherein T is C_1-C_6 alkyl.

30. The compound of any one of the preceding claims, wherein T is C_1-C_6 alkyl substituted with one or more halogen.

31. The compound of any one of the preceding claims, wherein T is -CHFCl.



32. The compound of any one of the preceding claims, wherein T is C_2-C_6 alkenyl.



33. The compound of any one of the preceding claims, wherein T is C_2-C_6 alkenyl substituted with one or more -OH, -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 10-membered heterocycloalkyl; wherein the 3- to 10-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.


34. The compound of any one of the preceding claims, wherein T is C_2-C_6 alkynyl.

35. The compound of any one of the preceding claims, wherein T is propynyl.

36. The compound of any one of the preceding claims, wherein T is propynyl substituted with one or more 3- to 10-membered heterocycloalkyl .

37. The compound of any one of the preceding claims, wherein T is , .

38. The compound of any one of the preceding claims, wherein T is , .



39. The compound of any one of the preceding claims, wherein at least one R^T is halogen.

40. The compound of any one of the preceding claims, wherein at least one R^T is CN, -OH, or $-NH_2$.

41. The compound of any one of the preceding claims, wherein at least one R^T is -O-(C_1-C_6 alkyl) or -N(C_1-C_6 alkyl)$_2$.

42. The compound of any one of the preceding claims, wherein at least one R^T is 3- to 10-membered heterocycloalkyl substituted with one or more C(=O)OH.

43. The compound of any one of the preceding claims, wherein at least one R^{Ta} is C(=O)OH.

44. The compound of any one of the preceding claims, wherein Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, $-NH_2$, $-OR^{A1a}$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1a};

each R^{A1a} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or $-NH_2$.


45. The compound of any one of the preceding claims, wherein Ar^1 is C_6-C_{10} aryl substituted with one or more R^{A1}.


46. The compound of any one of the preceding claims, wherein Ar^1 is phenyl substituted with one or more halogen.


47. The compound of any one of the preceding claims, wherein Ar^1 is phenyl substituted with one F and one Cl.


48. The compound of any one of the preceding claims, wherein Ar^1 is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with –O-(C_6-C_{10} aryl) or –O-(5- to 10-membered heteroaryl); wherein the –O-(C_6-C_{10} aryl) or –O-(5- to 10-membered heteroaryl) is optionally substituted with one or more halogen.


49. The compound of any one of the preceding claims, wherein Ar^1 is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with –O-phenyl or –O-pyridinyl; wherein the –O-phenyl or –O-pyridinyl is optionally substituted with one or more halogen.

50. The compound of any one of the preceding claims, wherein Ar^1 is 




, 


, 


, 


, or 

.

51. The compound of any one of the preceding claims, wherein Ar^1 is , , or .

52. The compound of any one of the preceding claims, wherein Ar^1 is 

or .

53. The compound of any one of the preceding claims, wherein Ar^1 is .

54. The compound of any one of the preceding claims, wherein at least one R^{A1} is halogen.

55. The compound of any one of the preceding claims, wherein at least one R^{A1} is F, and at least one R^{A1} is Cl.

56. The compound of any one of the preceding claims, wherein at least one R^{A1} is –O-phenyl or –O-pyridinyl; wherein the –O-phenyl or –O-pyridinyl is optionally substituted with one or more halogen.


57. The compound of any one of the preceding claims, wherein at least one R^{A1} is -O-CH_2-phenyl or -O-CH_2-pyridinyl, wherein the -O-CH_2-phenyl or -O-CH_2-pyridinyl is optionally substituted with one or more halogen.

58. The compound of any one of the preceding claims, wherein at least one R^{A1a} is phenyl or pyridinyl; wherein the phenyl or pyridinyl is optionally substituted with one or more halogen.

59. The compound of any one of the preceding claims, wherein at least one R^{A1b} is halogen.

60. The compound of any one of the preceding claims, wherein at least one R^{A1b} is F, and at least one R^{A1b} is Cl.


61. The compound of any one of the preceding claims, wherein the compound is of formula (II'):



(II'),

or a pharmaceutically acceptable salt or stereoisomer thereof.


62. The compound of any one of the preceding claims, wherein the compound is of formula (II'):




(II'),

or a pharmaceutically acceptable salt or stereoisomer thereof.

63. The compound of any one of the preceding claims, wherein the compound is of formula (III') or (III'-a):




(III'),




(III-a'),

or a pharmaceutically acceptable salt or stereoisomer thereof.

64. The compound of any one of the preceding claims, wherein the compound is of formula (IV') or (IV'-a):




(IV'),



(IV-a'),

or a pharmaceutically acceptable salt or stereoisomer thereof.

65. The compound of any one of the preceding claims, wherein the compound is of formula I



I

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

W is CH or N;

X^1 is –O–, –S–, $–NR^3–$;

R^a, R^b are independently of each other hydrogen, C_{1-4} alkyl or one of R^a is $–(CH_2)_p–$ which forms a ring with X^1 if X^1 is NR^3 or one of R^a is $–(CH_2)_p–$ which forms a ring with R^2

R^c, R^d are independently of each other hydrogen or C_{1-4} alkyl;

R^1 is H or F;

R^2 is hydrogen or C_{1-4} alkyl, or is $–(CH_2)_q–$ which forms a ring with R^3 or with one of R^a;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $–(CH_2)_p–$ which forms a ring with R^2;

m is 1, 2 or 3;


n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2 and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

66. The compound of any one of the preceding claims, wherein Ar^1 is of formula i or pharmaceutically acceptable salts or stereoisomers thereof




i

wherein

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl;

R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl.

67. The compound of any one of the preceding claims, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4 or pharmaceutically acceptable salts or stereoisomers thereof



ii-1 ii-2 ii-3 ii-4

wherein

X^2 is O, NH or NMe;

X^3 is CH or N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

68. The compound of any one of the preceding claims, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7 or pharmaceutically acceptable salts or stereoisomers thereof



iii-1 iii-2 iii-3 iii-4

iii-5 iii-6 iii-7

wherein

X^3 is CH or N, preferably N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;


R^5, R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.


69. The compound of any one of the preceding claims, wherein Ar^1 is of formula iv-1, iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9 or pharmaceutically acceptable salts or stereoisomers thereof




iv-1




iv-2




iv-3




iv-4




iv-5




iv-6



iv-7



iv-8



iv-9

wherein


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;


R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, -CF_3 or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

70. The compound of any one of the preceding claims, being of formula IIa or IIb



IIa



IIb

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

X^1 is –O– or –NR^3–;

R^1 is H or F;

R^2 is hydrogen or $C_{1\text{-}4}$ alkyl, preferably methyl or is –$(CH_2)_q$– which forms a ring with R^3;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $–(CH_2)_p–$ which forms a ring with R^2;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;


q is 0, 1 or 2;

r is 0 or 1;

s is 1 or 2; and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

71. The compound of any one of the preceding claims, being of formula III




III

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein


R^1 is H or F;

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, or C_6 aryl;

Z is selected from



72. The compound of any one of the preceding claims, being of formula IV



IV


or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;


R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl or C_6 aryl;

R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;


Z is selected from




73. The compound of any one of the preceding claims, being of formula V-1, V-2, V-3 or V-4




V-1



V-2



V-3



V-4

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

X^2 is O, NH or NMe;

X^3 is C or N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;


R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;


Z is selected from




74. The compound of any one of the preceding claims, being of formula VI-1, VI-2, VI-3 or VI-4




VI-1



VI-2



VI-3



VI-4

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

X^2 is O, NH or NMe;

X^3 is C or N;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;


R^7 is hydrogen or halogen, preferably F:

Z is selected from




.


75. The compound of any one of the preceding claims, being of formula VII-1, VII-2, VII-3 or VII-4, VII-5, VII-6 VII-7, VII-8 or VII-9




VII-1




VII-2




VII-3




VII-4




VII-5




VII-6



VII-7



VII-8



VII-9

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;


o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



.

76. The compound of any one of the preceding claims, being selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

77. A composition comprising to the compound of any one of the preceding claims, and a pharmaceutically acceptable carrier.

78. Use of the compound, pharmaceutically acceptable salts thereof, and stereoisomers thereof, of any one of claims 1-76 in the manufacture of a medicament for the inhibition of an oncogenic variant of an ErbB receptor.

79. Use of the compound, pharmaceutically acceptable salts thereof, and stereoisomers thereof, of any one of claims 1-76 in the manufacture of a medicament for the prevention or treatment of cancer.

80. The use of claim 79, wherein the cancer is a solid tumor.

81. The use of claim 79 or 80, wherein the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.

82. The use of any one of claims 79-81, wherein the cancer is glioblastoma (GBM) or any subtype thereof.

83. The use of any one of claims 79-81, wherein the cancer is glioblastoma.

84. The use of any one of claims 79-83, wherein the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an ErbB receptor.

85. The use of claim 78 or claim 84, wherein the oncogenic variant of the ErbB receptor comprises an allosteric mutation.

86. The use of claim 78 or claim 84, wherein the oncogenic variant of an ErbB receptor is is an allosteric variant of the ErbB receptor.

87. The use of any one of claims 78 or 84-86, wherein the oncogenic variant or the oncogenic mutation is detectable by a Food and Drug Aministration (FDA)-approved diagnosis.

88. Use of the compound, pharmaceutically acceptable salts thereof, and stereoisomers thereof, of any one of claims 1-76 in the manufacture of a medicament for the prevention or treatment of glioblastoma.

89. The use of any one of claims 78-88, wherein the compound is selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

90. The use of any one of claims 78-88, wherein the compound is selected from the compounds described in Tables 1 and 2 and pharmaceutically acceptable salts thereof.

91. The use of any one of claims 78-88, wherein the compound is selected from the compounds described in Table 1 and 2.